Bristol-Myers Squibb Company Q1 2026 Earnings Release and Financial Results

Bristol-Myers Squibb Company reported its financial results for the first quarter of 2026. Total revenues increased by 3% to $11.5 billion, with the Growth Portfolio revenues increasing by 12% to $6.2 billion. GAAP EPS was $1.31 and non-GAAP EPS was $1.58. The company reaffirmed its 2026 financial guidance, projecting revenues between $46.0 billion and $47.5 billion, and non-GAAP EPS between $6.05 and $6.35. Key product highlights include strong performance from Eliquis, Camzyos, Breyanzi, and Reblozyl. The company also provided updates on its pipeline, with several clinical data readouts and regulatory submissions expected throughout 2026 and beyond. Bristol-Myers Squibb is focused on driving R&D productivity, maintaining financial discipline, and strategically allocating capital to support long-term growth.